Methods: A single center retrospective chart review was performed on all CLI patients who underwent endovascular treatment for IP disease from 2006 to 2010. Patient and procedural variables were compared amongst IP CTOs and non-CTOs. Results: Baseline characteristics and procedural variables are depicted in table 1. Of 245 IP arteries intervened upon, 40% were CTOs. Mean CTO length was 100 mm and 21% had moderate to severe calcification. Successful recanalization was achieved in 82% of CTOs using standard guide wire and catheter technique. When compared to non-CTOs, CTOs were longer, had a lower number of concomitant patent run-off vessel(s) and more likely to undergo laser atherectomy and stent deployment. Predictor of failure to cross a CTO included moderate-severe calcification (44% vs. 15%, p ϭ 0.009) but not lesion length (103 vs. 108 mm, p ϭ 0.8.) 6 month target vessel revascularization (31% vs. 22%, p ϭ 0.4) and restenosis (48% vs 38%, p ϭ 0.3) rates were not significantly different between the CTO and non-CTO groups. One year major amputation rates (21% vs. 17%, pϭ0.4) were also similar between the two groups.
Background: There is considerable interest for the delivery of anti-proliferative drugs for the prevention of restenosis following intervention in patients with peripheral Artery disease. The TAPAS system (Thermopeutix, San Diego, CA) provides targeted fluid drug delivery between two occlusion balloons with an adjustable treatment zone. Following application, the drug may be aspirated to prevent systemic delivery. The purpose of this study was to evaluate the delivery of paclitaxel (PTX) to the vessel wall within the peripheral vasculature. Methods: Twelve pigs (nϭ 48 arteries) underwent treatment with fluid paclitaxel (Hospira, Lake Forest, IL) utilizing the TAPAS device for targeted drug delivery to the iliofemoral arteries. Three different concentrations of liquid PTX were tested: 0.67 mg/ml, 1.2 mg/ml and 2.0 mg/ml. PTX was diluted with saline and 50% contrast (Ultravist 300) to final concentration. The TAPAS catheter was positioned within the iliofemoral segment and drug was delivered in-between the system's dual occlusion balloons (nϭ4 target segments per animal). The drug was allowed to dwell for either 2 or 5 mins before aspiration. Animals were sacrificed at 3 and 24 hrs post treatment and the segments were dissected for analysis of PTX within the vessel wall. Plasma levels of PTX levels were also measured. Two additional pigs were treated with 2.0 mg/ml of PTX at a dwell time of 5 mins for histopathological assessment at 24 hrs post-treatment.
Results: PTX was detected in the vessel wall in all groups with no statistical differences between groups. The average PTX concentration in the vessel wall was 1.73 Ϯ 0.85 g/g and 1.29 Ϯ 0.47 g/g at 3 and 24 hrs post treatment, respectively. The average plasma PTX concentration was 2.36 Ϯ 0.50 ng/ml and 0.55 Ϯ 0.61 ng/ml at 3 and 24 hrs post treatment, respectively. Histology showed no inflammation, injury or other adverse effect vs. saline/ contrast control. On average, 77% of the total drug was aspirated from the treatment site.
Conclusions:
The TAPAS catheter can be used to successfully deliver paclitaxel to a target vessel segment with minimal systemic runoff and may be an alternative to drug eluting balloon. 1367 (6-19536) ] were independent predictors of medial smooth muscle cell loss. Unresorbed fibrin was found only in the PCB treatment, and proportionate to the number of consecutive PCB treatments (Ϸcumulative drug dose) but not to injury severity (at B:ARՅ1.25: PCBx2: 0.39Ϯ0.55 vs. PCBx6: 1.68Ϯ0.91, pϽ0.001); but at B:ARϾ1.25 it was not further aggravated (PCBx6: 2.08Ϯ0.42)]. This was confirmed by a significant correlation between fibrin deposition and the number of inflations (rϭ0.77, pϽ0.001) but not with injury severity (rϭ-0.11, pϭ0.1). Interestingly, medial-intimal inflammation was observed with multiple treatments regardless of PCB or control, while adventitial inflammation was noted with excess injury, also regardless of treatment type (B:ARϾ1.25, Table) . Conclusions: Adverse effects of PCB such as aneurysmatic dilatation are most evident when arterial injury is excessive. Multiple PCBs deployed in the same segment (and as such the incremental cumulative drug dose) are well tolerated if the arterial injury is contained. 
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